A 12 week, multi-center, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of SCE on atopic dermatitis in childre
Not Applicable
Recruiting
- Conditions
- Diseases of the skin and subcutaneous tissue
- Registration Number
- KCT0002233
- Lead Sponsor
- ovarex
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1)subject who signs Informed Consent Form with a legal representative who signs the informed consent form before participating in the study
2)subject aged between 3 years and 12 years with atopic dermatitis
3)subject with intermittent or continuous atopic dermatits symptom over 6 months
4)subject with SCORing of Atopic Dermatitis index between 25 and 50
Exclusion Criteria
1)subject with other systemic illnesses or dermatits history except Atopic Dermatitis
2)subject administrating immunosuppressant,antobiotics,corticosteroid, antihistaminic within 4 weeks
3)subject who has taken medicines,chinese medicine, health functional foods within 4 weeks for improvement of atopic dermatitis
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SCORing of Atopic Dermatitis score
- Secondary Outcome Measures
Name Time Method SCORing of Atopic Dermatitis objective score;SCORing of Atopic Dermatitis subjectiv score;Investigator’s Global Assessment